跳至主要内容
临床试验/NCT06499012
NCT06499012已完成不适用

A Randomized, Double-blind Clinical Study of the Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly People

Amway (China) R&D Center2 个研究点 分布在 1 个国家目标入组 139 人开始时间: 2025年7月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
139
试验地点
2
主要终点
Change of SPPB Score from baseline

研究概览

简要总结

The goal of this clinical trial is to learn whether Amway Nutrilite All-plant protein booster prototype product (test product) will improve sarcopenia (SA) and osteoarthritis (OA) in middle-aged and elderly people. It will also learn about the improvement of Quality of life (QoL) in them. The main questions it aims to answer are:

  • Does the test product will improve the SA in terms of Short Physical Performance Battery (SPPB score) after 12 weeks' intervention?
  • Does the test product will improve the OA in terms of Western Ontario and McMaster Universities Arthritis (WOMAC Index) after 12 weeks' intervention?

Researchers will compare Amway All-plant protein booster prototype product to a placebo (a look-alike substance that contains no similar active nutrient ingredients) to see if the test product works to improve SA and OA.

Participants will:

  • Take the test product or a placebo 2 spoons (15g) twice per day for 12 weeks
  • Visit the site on the baseline day and the 84th day (end day of 12 weeks) for checkups and tests

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
50 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be age 50 to 70 years, female and male
  • Participants will be required to have mild to moderately OA & SA evaluated by Kellgren-Lawrence I-II and SARC-Cal, respectively
  • Participants need to be competent i.e., able to understand what is to take place and able to provide a free decision on agreeing to the activity/taking part on the study on this
  • Participants must be able to read and understand study instructions and any other relevant study documents
  • Willing to following the lifestyle restrictions as detailed in the Information Sheet for study
  • Will to give written informed consent

排除标准

  • Have a fever currently, or for 24 hours before enrollment
  • Currently participating in another clinical study
  • Have taken other protein powder products and dietary supplements or medicines containing peptides or hyaluronic acid within the past 6 months (subject to product instructions)
  • Individuals receiving medical treatment that, in the opinion of the Principal Investigator or Study Physician, may interfere with test results
  • The participant is an employee of Amway or SPRIM Medical
  • Subject who is in the treatment of gastrointestinal diseases
  • Subject with abnormal liver function tests (alanine aminotransferase and aspartate aminotransferase), kidney function tests (blood urea nitrogen and creatinine), blood routine, urine routine, fecal occult blood test, or electrocardiogram.
  • Subjects have any of the following medical history or have been clinically examined to have the following diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases

结局指标

主要结局

Change of SPPB Score from baseline

时间窗: baseline day 0, week 12

The SPPB (Short Physical Performance Battery) test is a group of measures that combines the results of the gait speed, chair stand and balance tests (Guralnik et al., 2000). lt has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance).

Change of WOMAC 3.1 index from baseline

时间窗: baseline day 0, week 12

The WOMAC (Western Ontario and McMaster Universities Arthritis) Index was created to assess pain, stiffness, and physical function in patients with hip and / or knee osteoarthritis (OA). The WOMAC 3.1 consists of 24 items divided into 3 subscales. The scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68. A total WOMAC score is created by summing the items for all three subscales. (0-96), higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

次要结局

  • Improvement of Quality of Life by Chalder Fatigue Scale (CFQ 11)(baseline day 0, week 12)
  • Change of SFQ from baseline(baseline day 0, week 12)
  • Change of bone density measured by DXA Bone Densitometer from baseline(baseline day 0, week 12)
  • Improvement of Fat and Muscle Portions measured by Inbody S10 from baseline(baseline day 0, week 12)
  • Improvement of Quality of Life by WHOQOL BREF(baseline day 0, week 12)
  • Improvement of Quality of Life by SF-36(baseline day 0, week 12)

研究者

发起方
Amway (China) R&D Center
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验